Last reviewed · How we verify

Lori Davis, MD — Portfolio Competitive Intelligence Brief

Lori Davis, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Adjunctive asenapine Adjunctive asenapine marketed Atypical antipsychotic D2 dopamine receptor, 5-HT2A serotonin receptor Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Acacia Pharma Ltd · 1 shared drug class
  2. Alexza Pharmaceuticals, Inc. · 1 shared drug class
  3. Alkermes, Inc. · 1 shared drug class
  4. All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Benaroya Research Institute · 1 shared drug class
  7. BioXcel Therapeutics Inc · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lori Davis, MD:

Cite this brief

Drug Landscape (2026). Lori Davis, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lori-davis-md. Accessed 2026-05-14.

Related